Astellas to acquire Ocata

Astellas Pharma has entered into a definitive agreement to acquire Ocata Therapeutics, according to a press release. Astellas will acquire Ocata through Laurel Acquisition, a wholly owned subsidiary of Astellas. Laurel will commence a tender offer for all outstanding shares of Ocata’s common stock for $8.50 per share in cash.